Evidence map›Paper›PMID 42065131›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Ring-Opening Arylation of Cyclic Diaryliodoniums via Cyclic Triaryliodanes as Aryne Precursors and Dynamic Aryl Reservoirs.

Daichi Ikeshita, Mao Atarashi, Naohiko Yoshikai

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daichi IkeshitaGraduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Mao AtarashiGraduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Naohiko YoshikaiGraduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.ORCID https://orcid.org/0000-0002-8997-3268

Funding

Asahi Glass FoundationBasis for Supporting Innovative Drug Discovery and Life Science Research (BINDS JP25ama121040Daiichi Sankyo FoundationJSPS KAKENHI JP24K01478JSPS KAKENHI JP24KJ0447Life Science and Drug DiscoveryNaito FoundationResearch Support ProjectTohoku University
6 · The paper itself

Abstract

Cyclic diaryliodonium salts are widely employed as linchpins for constructing functionalized biaryls and as precursors to arynes under basic conditions. However, their synthetically practical engagement with strongly nucleophilic organometallic reagents has remained largely unexplored. Here we disclose a reaction between these salts and aryl Grignard reagents that delivers iodine-capped teraryls with predominant meta-selectivity. In contrast to ligand coupling at iodine(III) or direct base-induced aryne formation, the present transformation is initiated by the formation of a cyclic triaryliodane, which serves as both an aryne precursor and a dynamic aryl reservoir within a self-propagating carbomagnesiation sequence. Spectroscopic analyses and control experiments support the involvement of the triaryliodane and reversible aryl exchange with aryl Grignard reagents, while trapping experiments intercept both aryne and terarylmagnesium intermediates. The reaction tolerates sterically and electronically diverse aryl Grignard reagents with consistent meta-selectivity, whereas strongly perturbing substituents on the iodonium salts can modulate the regioselectivity. The resulting iodo-teraryls retain a versatile C─I bond amenable to further π-extension or recyclization into cyclic iodonium architectures.

Indexed as

arynesGrignard reagentshypervalent iodine compoundsoligoarylsreaction mechanism

Identifiers

PMID42065131
PMCPMC13245596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.